12,372 trials
Pneumonia, Viral
Primary: Proportion of Patients Alive and Free of Respiratory Failure at Day 28 — 152; 71 participants — p=0.216
Allergic Rhinitis Due to Dermatophagoides Farinae · Allergic Rhinitis Due to Dermatophagoides Pteronyssinus · Allergic Rhinitis Due to House Dust Mite
Primary: Average Daily Total Combined Rhinitis Symptom and Medication Score (TCRS) During the Primary Efficacy Assessment Period — 3.4; 4.4 score on a scale — p=<0.0001
Multiple Sclerosis, Relapsing-Remitting
Primary: Part 1: Mean Number of New or Newly Enlarging T2 Hyperintense Lesions at Week 72 — 0.05; 0.20 number of T2 lesions — p==0.0755
Desmoid Tumor · Aggressive Fibromatosis
Primary: Progression Free Survival (PFS) Defined as the Time From Randomization Until Date of Assessment of Progression or Death by Any Cause. — NA; 15.1 Months — p=< 0.001
Uterine Atony · Uterine Atony With Hemorrhage · Postpartum Hemorrhage
Primary: Quantitative Blood Loss — 840; 1051 milliliters — p=<0.05
Obesity
Primary: Change in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) — 16.8; 10.3 Score on a scale — p=<0.0001
Cystic Fibrosis
Primary: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) — 0.3; 0.5 percentage points — p=< 0.0001
Atopic Dermatitis
Primary: VC Period: Percentage of Participants Who Achieved Investigator's Global Assessment - Treatment Success (IGA-TS) at Week 8 — 10.8; 36.6; 56.5 percentage of participants…
Pneumococcal Infection
Primary: Percentage of Participants With Solicited Injection-site Adverse Events (AEs) — 5.4; 6.3; 15.5; 13.0 Percentage of participants
Dry Eye
Primary: Number of Patients Reaching a Value of Schirmer I Test (Without Anaesthesia) >10mm/5min at Week 4 — 19; 2 Participants — p=<0.001
Trypanosomiasis, African · Sleeping Sickness · Trypanosomiasis; Gambian
Primary: Percentage of Participants Whose Treatment Outcome at Month 18 is a Success — 93.1 percentage of participants
Axillary Hyperhidrosis
Primary: Number of Participants (Vehicle Arm vs. Sofpironium Bromide Gel, 15%) With and Without an Observed ≥2-point Improvement in Hyperhidrosis Disease Severity…
Macular Edema · Retinal Vein Occlusion
Primary: Mean Change in Best Corrected Visual Acuity (BCVA) From Day 1 to Week 24 in BRVO Participants. — 14.2; 15.6 ETDRS Letters — p=.0004
Prader-Willi Syndrome
Primary: Change From Baseline to Month 12 in Lean Body Mass Measured by Dual-Energy X-ray Absorptiometry (DEXA): Adult Cohort — 3.09 Percentage of body mass
Nutrition Disorder · Trauma · Critical Illness
Primary: Serum Concentrations of Transthyretin at 3 Weeks After Injury. — 18.1; 18.9 mg/dl